tadalafil has been researched along with Depression in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Jeong, TY; Kim, KS; Moon, HS | 1 |
| Deyo, RA; Dobscha, SK; Donovan, M; Johnson, ES; Morasco, BJ; Petrik, A; Smith, DH; Tillotson, CJ; Yang, X | 1 |
| Brand, L; Brink, CB; Harvey, BH; Liebenberg, N | 1 |
| Baek, SB; Bahn, G; Kim, BK; Kim, CJ; Kim, KH; Kim, SE; Kim, TS; Ko, IG; Lee, J; Moon, SJ; Shin, MS; Sung, YH | 1 |
| Elkin, S | 1 |
| Ahuja, S; Goldstein, I; Kim, E; Natanegara, F; Pryor, JL; Steers, WD; Wilde, DW; Wong, DG | 1 |
1 trial(s) available for tadalafil and Depression
| Article | Year |
|---|---|
Efficacy and safety of tadalafil in men with erectile dysfunction with a high prevalence of comorbid conditions: results from MOMENTUS: multiple observations in men with erectile dysfunction in National Tadalafil Study in the US.
Topics: Age Distribution; Aged; Carbolines; Comorbidity; Depression; Diabetes Mellitus; Dose-Response Relationship, Drug; Erectile Dysfunction; Humans; Hypertension; Male; Middle Aged; Penile Erection; Phosphodiesterase Inhibitors; Prevalence; Tadalafil; Treatment Outcome; United States | 2007 |
5 other study(ies) available for tadalafil and Depression
| Article | Year |
|---|---|
Effect of daily tadalafil on reported outcomes in patients with erectile dysfunction and depressive symptoms: STROBE, a case-control study.
Topics: Adult; Aged; Case-Control Studies; Depression; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Prospective Studies; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Tadalafil; Young Adult | 2020 |
Prescription opioids for back pain and use of medications for erectile dysfunction.
Topics: Adult; Age Factors; Aged; Analgesics, Opioid; Androgens; Back Pain; Carbolines; Comorbidity; Cross-Sectional Studies; Depression; Drug Prescriptions; Erectile Dysfunction; Hormone Replacement Therapy; Humans; Imidazoles; Insurance, Health; Logistic Models; Male; Middle Aged; Piperazines; Prevalence; Purines; Sildenafil Citrate; Smoking; Sulfones; Tadalafil; Testosterone; Triazines; United States; Urological Agents; Vardenafil Dihydrochloride | 2013 |
Antidepressant-like properties of phosphodiesterase type 5 inhibitors and cholinergic dependency in a genetic rat model of depression.
Topics: Animals; Antidepressive Agents; Atropine; Behavior, Animal; Carbolines; Depression; Disease Models, Animal; Dose-Response Relationship, Drug; Fluoxetine; Male; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Rats; Sildenafil Citrate; Sulfones; Swimming; Tadalafil | 2010 |
The phosphodiesterase type-5 inhibitor, tadalafil, improves depressive symptoms, ameliorates memory impairment, as well as suppresses apoptosis and enhances cell proliferation in the hippocampus of maternal-separated rat pups.
Topics: Age Factors; Animals; Animals, Newborn; Apoptosis; Avoidance Learning; Bromodeoxyuridine; Carbolines; Caspase 3; Cell Proliferation; Dentate Gyrus; Depression; Disease Models, Animal; DNA Fragmentation; Female; Freezing Reaction, Cataleptic; In Situ Nick-End Labeling; Maternal Deprivation; Memory Disorders; Phosphodiesterase 5 Inhibitors; Pregnancy; Rats; Rats, Sprague-Dawley; Reaction Time; Swimming; Tadalafil | 2011 |
In that case.
Topics: Advertising; Carbolines; Confidentiality; Depression; Erectile Dysfunction; Female; Humans; Male; Phosphodiesterase Inhibitors; Piperazines; Professional-Family Relations; Purines; Sildenafil Citrate; Spouses; Sulfones; Tadalafil | 2005 |